SLC5A2 and polycystic ovary syndrome: Therefore, novel pharmacotherapies, such as sodium-glucose cotransporter-2 inhibitors, could simultaneously target multiple mechanisms of the pathophysiology of the cardiometabolic complications associated with PCOS.